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Here, we present results from a clinical trial employing a new vaccination method using dendritic cells (DCs) transfected with mRNA
from allogeneic prostate cancer cell lines (DU145, LNCaP and PC-3). In all, 20 patients were enrolled and 19 have completed
vaccination. Each patient received at least four weekly injections with 2 10
7 transfected DCs either intranodally or intradermally.
Safety and feasibility of vaccination were determined. Immune responses were measured as delayed-type hypersensitivity and by in
vitro immunoassays including ELISPOT and T-cell proliferation in pre- and postvaccination peripheral blood samples. Serum prostate-
specific antigen (PSA) levels and bone scans were monitored. No toxicity or serious adverse events related to vaccinations were
observed. A total of 12 patients developed a specific immune response to tumour mRNA-transfected DCs. In total, 13 patients
showed a decrease in log slope PSA. This effect was strengthened by booster vaccinations. Clinical outcome was significantly related
to immune responses (n¼19, P¼0.002, r¼0.68). Vaccination with mRNA-transfected DCs is safe and results in cellular immune
responses specific for antigens encoded by mRNA derived from the prostate cancer cell lines. The observation that in some patients
vaccination affected the PSA level suggests that this approach may become useful as a treatment modality for prostate cancer
patients.
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Prostate cancer is one of the most common types of cancer in
Western countries, and is the second leading cause of cancer death
in men after lung cancer. Patients with metastatic disease usually
receive palliative hormone treatment. Still, most of these patients
will eventually develop hormone-refractory disease with increasing
prostate-specific antigen (PSA) levels. Cancer vaccines may
represent an alternative form of therapy for such patients. It has
been shown that autologous dendritic cells (DCs) pulsed with
peptides specific for PSA (Heiser et al, 2000), prostate-specific
membrane antigen (PSMA) (Tjoa et al, 1996) or telomerase reverse
transcriptase (TERT) (Vonderheide et al, 1999) are capable of
stimulating potent CTL responses in vitro and data from clinical
trials are now available (Heiser et al, 2002; Kaufman et al, 2004).
Since prostate cancer cells are genetically unstable and as such
represent ‘shifting targets’ (Shaffer and Scher, 2003), single-agent
vaccines may result in selection of genetic variants that escape the
immune attack. The use of vaccines containing multiple tumour-
derived antigens may elicit a broader antitumour response than
single antigen vaccines and circumvent to some extent the problem
of immune escape (Heiser et al, 2001).
Several strategies for whole tumour vaccines are available.
Fusion between autologous tumour cells and allogenic DCs has
recently been used as semiallogeneic tumour vaccines in clinical
trials (Gong et al, 2000; Trefzer et al, 2000). For hormone-resistant
prostate cancer patients with increasing PSA, tumour cells are
generally not available for this approach. An alternative to
autologous tumour material would thus be the use of allogeneic
prostate cancer cell lines. In a rat model, the prophylactic use of
allogeneic tumour vaccination resulted in tumour protection of the
animals (Hrouda et al, 2000). A similar approach has recently been
used in humans (Eaton et al, 2002). Dendritic cells pulsed with
lysates of allogeneic prostate cancer cell lines has also been tested
in a phase I/II clinical study (Pandha et al, 2004). Recently, we have
developed a clinical scale method for GMP (good manufacturing
practice) production of allogeneic mRNA-transfected DC as an
alternative approach (Mu et al, 2003). We here present data from
our first clinical study, indicating that the treatment is safe and
results in specific immune responses as well as decrease of PSA
level in a majority of the patients.
MATERIALS AND METHODS
Patient selection
Inclusion criteria were histologically verified adenocarcinoma of
the prostate with evidence of disease progression as assessed by
Received 5 May 2005; revised 29 June 2005; accepted 2 August 2005;
published online 30 August 2005
*Correspondence: Dr G Gaudernack;
E-mail: gustav.gaudernack@labmed.uio.no
British Journal of Cancer (2005) 93, 749–756
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sincreasing PSA in three subsequent analyses while on LHRH
agonist, or following orchiectomy with or without antiandrogen
medication. All patients had their antihormonal treatment
continued through the vaccination period and 3 months following
the therapy. Age 445 years with ECOG performance score o2,
adequate haematologic, renal and hepatic function was required
(details not shown). Prior radiotherapy and chemotherapy must
have elapsed a minimum of 4 weeks prior to entry in the study.
Patients with a history of disease not suitable to vaccines were
excluded. Patients in the two arms of this study (intradermal (i.d.)
or intranodal (i.n.) injection) were included on a consecutive basis
and were not stratified. The trial was approved by the Norwegian
Medicines Agency, the Norwegian Department of Health Gene
Therapy Board and the Regional Committee for Medical Research
Ethics, and performed in compliance with the Helsinki declaration.
Written informed consent was obtained from all patients.
Preparation of mRNA-transfected DCs
Monocyte-derived DCs were generated as described previously
(Mu et al, 2003). Briefly, peripheral blood mononuclear cells
(PBMC) obtained by leukopheresis were enriched for monocytes
by immunomagnetic depletion of B cells and T cells using ISOLEX
300i magnetic cell selector (Nexell, Irvine, CA, USA). After 5 days
culture in Teflon bags, using serum-free CellGro DC medium
(CELLGenix, Freiburg, Germany) supplemented with granulocyte/
macrophage colony-stimulating factor (2500Uml
 1) and inter-
leukin-4 (IL-4, 1000Uml
 1) (CELLGenix), immature DCs were
generated. Bulk tumour mRNA was extracted from three human
prostate cancer cell lines DU145, LNCaP and PC-3 (obtained from
ATCC, Manassas, VA, USA) corresponding to 5 10
7 cells of each
type for each vaccine preparation and mixed before transfection. A
square-wave electroporation procedure was employed to transfect
mRNA (120ml, 0.2–1mgml
 1) into immature DCs. Quality of all
RNA preparations were controlled by electrophoresis on agarose
gels stained by Gel star (Cambrex Bio Science, Verviers, Belgium).
Selected mRNA preparations were also evaluated on an Agilent
Bioanalyser instrument using RNA 6000 Nano Reagent & Supplies
(Agilent Technologies, Palo Alto, CA, USA). The Bioanalyser
quantifies RNA by calculating size and concentration of each
separated band (Kyte et al, 2005). Transfection efficiency was
monitored in separate experiments with enhanced green fluo-
rescent protein mRNA instead of tumour mRNA as described (Mu
et al, 2003). Cells were matured for 48h, using the same medium
supplemented with IL-1b (10ngml
 1), IL-6 (1000Uml
 1), tumour
necrosis factor a (10ngml
 1) (CELLGenix) and prostaglandin E2
(1mgml
 1) (Sigma-Aldrich, USA). Mature DCs were then frozen in
aliquots containing 2 10
7vial
 1 and stored in liquid nitrogen
until use. Mock-transfected DCs were cultured following the same
electroporation procedure without mRNA and frozen as described
above. Cell quality including phenotype, viability and sterility were
monitored for each step.
DC vaccination
Frozen mRNA-transfected DCs were thawed in a 371C water bath,
washed once and resuspended in 200ml PBS for vaccination. Each
patient received at least four weekly injections employing 2 10
7
DCs each time. Of the 20 patients being enrolled, 10 of them had
the DCs injected by ultrasound guidance directly into the
paracortex of an inguinal lymph node (i.n.), while the others
received the vaccine i.d.
Evaluation of immune responses
Blood samples were taken from patients before vaccination
(baseline), 5 weeks and 3 months after the start of vaccination
(Figure 1). PBMC were isolated and frozen in liquid nitrogen until
testing.
T-cell proliferation test The T-cell-enriched nonadherent fraction
of PBMC was obtained by a plastic adherence step and used as
responder cells. Irradiated (30Gy) tumour mRNA-transfected DCs
(DCt) and mock-transfected DCs (DCn) were used as stimulators.
Responder cells 5 10
4well
 1 were cultured in triplicate with
various numbers of stimulators for 5 days at 371C, 5% CO2 in
CellGro DC medium.
3H-thymidine (Laborel, Oslo, Norway) was
added 18h before testing. Data were reported as counts per minute
(c.p.m.). Medium only, responder cells only and stimulator cells
only were used as negative controls.
ELISPOT assay The same responder and stimulator cells as
described above were used. Dendritic cells as stimulators were
plated 4 10
3well
 1, while the responder cells were added in a
titration from 1 10
5well
 1 to 1.25 10
4well
 1 in duplicate.
Details have been described previously (Mu et al, 2003). Spots
per 10
5 T cells were calculated. Results were recorded positive
when the mean number of spots in the DCt wells differed
significantly from that of the DCn.
Generation of T-cell clones and specificity test T-cell clones were
generated from responder cells that gave a positive proliferation
response. Cells were incubated in CellGro DC medium by limiting
dilution (0.3/1/3 cellswell
 1). Irradiated (30Gy) allogeneic PBMC
(10
6ml
 1) were used as feeder cells, and 1mgml
 1 PHA and
20Uml
 1 IL-2 were added. Clones obtained were tested by
proliferation test described above and also by a standard
51Cr
cytotoxicity test (Heiser et al, 2001). For cytotoxicity assay, DCt,
DCn and prostate cancer cell lines DU145, LNCaP and PC-3,
respectively, were used as targets.
Delayed-type hypersensitivity (DTH) reaction Tumour mRNA-
transfected DCs and DCn were administered to patient i.d. in week
5 at separate sites. The diameters of the erythema were measured
and recorded by the patient 48h after injection. Since skin
reactions also regularly developed towards the DCn, it was
accordingly scored as positive when the erythema diameter of DCt
was X10mm and also at least 5mm bigger than that of the DCn.
Clinical monitoring
Assessment of safety Adverse events were evaluated and graded
according to the standard criteria (NCI-CTC criteria version 2.0).
The relation between adverse events and treatment was also given
as probable, suspected, unlikely or not related to treatment.
Adverse events were considered as being related to the treatment if
the relationship was reported as probable or suspected.
Assessment of clinical response Clinical progression was defined
as the appearance of new lesions of malignant disease, or the
development of symptoms consistent with metastatic disease.
DC  DC  DC  DC 
–1w 1w 2w 3w 5w 12w 0
PBMC PBMC PBMC
PSA PSA PSA
Bone scan DTH Bone scan
Figure 1 Flow chart of trial.
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sResponse was also assessed as PSA levels in serum. PSA
measurements were carried out before therapy, at week 5 and
month 3 after the start of vaccination. A partial PSA response was
defined as a reduction of PSA by greater than 50% from baseline,
stable disease was defined as a reduction of less than 50% or an
increase of less than 50%, and progressive disease was defined as
an increase of greater than 50% (Kaufman et al, 2004).
Statistical analysis
The pre- and postvaccination data were assessed by two-way
ANOVA (SPSS). The linear regression model was used to obtain
estimates of the change in serum PSA over time. Statistical
significance was determined at Po 0.05. All statistical tests were
two-sided.
RESULTS
Patient characteristics
In this study, DCs were prepared from 20 patients. Of these, 19
patients completed four vaccinations, while one discontinued due
to tumour progression before vaccination was initiated. The
characteristics of the 19 patients are summarised in Table 1. All
patients had hormone-resistant disease with increasing PSA levels
and 14 patients had bone metastases at the time of inclusion. At
the start of treatment, five patients had anaemia grade I and four
patients had hypoalbuminaemia grade I. One patient had serum
aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) levels grade I and another patient had serum creatinine level
grade I. The rest of the patients had haemoglobin, albumin, AST,
ALT and creatinine within normal levels. All patients had bilirubin
within normal levels as well as total number of white cells,
neutrophils and platelets above lower normal limits. All the
patients with anaemia and or hypoalbuminaemia had positive
bone scans at the start of treatment.
Safety of DC therapy
In this study, 10 patients received i.n. vaccinations, while the other
nine patients received i.d. injections. At least four vaccine doses
were administrated to each patient. Five patients also received
boost injection (P08, P10, P16, P17 and P19). Vaccination was well
tolerated with no grade II–IV toxicity. Minor symptoms related to
the vaccination treatment were erythema and increased size of
groin lymph nodes at the injection site, minor pain at the injection
site or a small increase in hot flushes. These symptoms were seen
in only a few of the patients and were considered negligible.
Between the end of vaccination and evaluation at the 3rd month
after the start of treatment, one patient started Taxotere treatment
at another clinic. Blood tests showed no treatment-related
neutropenia, thrombocytopenia, renal or liver toxicity. All the six
patients with anaemia at the 3rd month had positive bone scans.
Production and quality testing of mRNA-transfected DCs
After B- and T-cell depletion, blood samples contained a mean
value of 53.1%. (27–65%) CD14þ cells, 1.3% (0–10%) B cells and
5.4% (1–9%) T cells. Following culture procedure including
electroporation, the produced cells showed mature DC morpho-
logy and phenotype characterised by no or very low proportion of
CD14, but high expression of CD86 and HLA-DR with variable
expression of CD83 (Table 2). Thawing and washing of the frozen
samples gave a mean viability of 86.6% (56–98%), with a mean cell
yield of 8.2% (1.9–19.6%) of the total PBMC used.
Table 2 Vaccine characteristics and results
Patient ID
Vaccine
route
Quality of DC
%CD83/%CD86/ %HLA-DR
Number of
vaccinations DTH
Immune
response
Log PSA
slope
a
Clinical
outcome
P01 i.n. 27.8/98.7/95.2 4      PD
b
P02 i.n. 25.7/92.6/81.7 4 NT   +S D
b
P03 i.n. 34.0/95.8/89.3 4   ++ S D
P04 i.n. 13.1/96.1/88.3 4    +P D
b
P05 i.n. 44.7/97.7/91.9 4 + + + SD
b
P06 i.n. 11.1/94.3/93.6 4 +   +P D
b
P07 i.n. 91.4/94.4/96.1 4 NT    PD
b
P08 i.n. 91.0/99.7/99.8 5 + + + SD
b
P09 i.n. 97.0/99.7/98.6 4 NT    PD
b
P10 i.d. 94.6/99.5/97.8 5 + +   PD
b
P11 i.d. 72.7/92.5/88.1 4   +   SD
b
P12 i.d. 92.0/99.0/96.3 4   ++ S D
b
P13 i.d. 86.0/97.0/89.7 4   ++ S D
P14 i.d. 90.5/99.0/96.6 4 + + + PD
b
P15 i.d. 95.7/98.8/99.3 4   ++ S D
b
P16 i.d. 94.8/98.8/98.4 6   ++ S D
P17 i.d. 84.8/99.6/97.3 5   ++ S D
P19 i.n. 90.6/99.4/97.0 6   ++ S D
b
P20 i.d. 96.1/98.5/97.2 4      PD
DC¼dendritic cells; DTH¼delayed-type hypersensitivity; PSA¼prostate-specific antigen; i.n.¼intranodal; i.d.¼intradermal; NT¼not tested; SD¼stable disease;
PD¼progressive disease.
aDecrease in slope marked as ‘+’.
bIndicate the patient is positive in bone scan.
Table 1 Patient characteristics
Characteristics Value
Age (years) (median, range) 69 (48–78)
Stage of disease when diagnosed
a
T2 4
T3 15
Gleason score (median, range) 8 (7–9)
Interval between diagnosis and vaccination (median, range)
b 56 (19–153)
Baseline PSA (median, range)
c 50 (7.9–2571)
Bone scan positive before vaccine 14
PSA¼prostate-specific antigen.
aTwo of them were N1M0, 12 were N0M0 and five
were NxMx.
bMonths.
cMicrogram per litre.
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Of 19 patients treated, 10 showed positive response in the ELISPOT
test. Result recorded in Figure 2 represents number of spots per
10
5 T cells in the assay. The mean frequency of specific T cells after
vaccination was calculated to be 18.8/10
5 T cells (range 6–50/10
5
T cells), which represents a 14-fold increase compared with
prevaccine samples. Of the responding patients, three were given
i.n. administration and seven were injected i.d. Following
vaccination, T cells from most patients also showed stronger
response to DCn than what was found prior to vaccination,
suggesting that a considerable autologous mixed lymphocyte
reaction (MLR) was generated during the vaccination. Even with
this MLR component obscuring the specific response, a significant
proliferation response specific for DCt was observed in nine
patients (Figure 3), seven of these were also ELISPOT positive.
Compared to T cells from prevaccine samples, postvaccine T cells
showed a clear dose-dependent response with increasing numbers
of DCswell
 1. The emergence of both an MLR response as well as
specific T-cell response following vaccination is evident. A decline
in T-cell proliferation was usually observed over the next 3 months
compared to the responses on week 5, but the immune response
could be boosted by the administration of additional vaccine
injections (data not shown).
T-cell clones were generated from patients with a positive
response. Figure 4A shows results of proliferation test of T-cell
clones derived from P19. These clones generated from postvaccine
T cells were considered specific for antigens encoded by tumour–
mRNA since they responded significantly to DCt. All of the clones
were CD4þ confirmed by flow cytometry. From patient 10, 46
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Figure 3 T-cell proliferation test from the nine patients with positive result. T0: T cells from before vaccine; T5: T cells from the 5th week after vaccine.
DCt: tumour mRNA-transfected DC; DCn: mock-transfected DC. Results are recorded as mean c.p.m. of triplicate with 95% confidential interval (CI)
indicated on the bars.
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Figure 2 ELISPOT result in the10 patients with positive response. Data
show INFg spots per 10
5 T cells. T0: T cells from before vaccine; T5: T cells
from the 5th week after vaccine. DCt: tumour mRNA-transfected DC;
DCn: mock-transfected DC. Results are recorded as mean number of INFg
spots with 95% confidential interval (CI) indicated on the bars.
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sT-cell clones were generated, two of which were CD8þ. Patient 10
shared the HLA-A9 antigen with the tumour cell line PC-3. We
accordingly tested if these potential CTL clones would recognise
this cell line in a standard cytotoxicity assay using DCn and DCt as
negative and positive controls. HLA-A9-matched Epstein–Barr
virus (EBV)-transformed B-cell lines (WT51 (HLA-A23) and BRIP
(HLA-A24)) from the 10th IHWS homozygous cell panel were also
used as control target. The results depicted in Figure 4B
demonstrate that these CTL clones specifically killed DCt and
more efficiently also the PC-3 cell line, but did not lyse EBV cells.
In separate experiments, no killing of the two other cell lines used
for preparation of mRNA was observed (data not shown). Taken
together, these results demonstrate that vaccination with DCt gives
rise to a broad T-cell response including both the CD4þ and the
CD8þ T-cell subsets.
Delayed-type hypersensitivity
Five of the 19 tested patients were positive in the DTH test
(Table 2). For three patients, DTH result was not available. Median
erythema diameter of the DTH-positive patients was 17mm (10–
62mm). Considerable DTH reactivity against DCn was also
developed during vaccination, necessitating a stringent definition
of a positive response. This probably made the results of the DTH
response less informative.
Clinical response
Although the primary goal of this phase I/II trial was to assess
safety and immune responses to the DC vaccine, patients were also
assessed for early clinical response registered 3 months after entry
into the vaccine trial (Table 2).
No improvement in bone scan was observed. However, patients
with positive bone scan prior to therapy disclosing immunological
response had unchanged bone scans 3 months after therapy. By
PSA response criteria, 11 patients fell into the criteria of stable
disease. Six patients (P02, P03, P05, P11, P13, and P14) showed a
0.6–48.7% decrease of serum PSA value. Although the absolute
PSA value continued to rise in most of the patients, a decrease of
log slope PSA (PSA velocity) after vaccination was noted in 13
patients out of 19 patients (Figure 5). Figure 6 shows log PSA
measurements at different time points in four representative
patients, among whom three were given one to two additional
boost injection(s). Before vaccination, all patients had a log-linear
rising serum PSA. Following vaccination, the rising slope
decreased (P16), kept stable (P08, P19) or became negative
(P05). In the three patients given boost injection(s), the log slope
PSA decreased further indicating that biochemical response comes
late and that such patients may need to be boosted for a longer
time period. Among the 11 patients with evidence of disease
stabilisation on the 3rd month, 10 had developed specific T-cell
response, while only two of eight patients with disease progression
showed T-cell response. Thus, a clear correlation between immune
response and early clinical response was established (n¼19,
P¼0.002, r¼0.68).
DISCUSSION
The present study describes the results of a phase I/II clinical study
of a vaccine based on allogeneic tumour mRNA transfected
autologous DC in advanced prostate cancer. There is growing
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Figure 4 (A) Proliferative responses of Th clones from patient 19. In all,
72 T-cell clones were generated from postvaccine T cells, of these 10 were
specific for transfected DC. All were of the CD4þ phenotype. Seven
representative positive clones are shown here. Results are given as mean
c.p.m. of triplicate wells with standard error of the mean (s.e.m.) indicated
on the bars. (B) Killing of
51Cr target cells by CTL clones derived from
patient 10. Two of CD8þ clones were derived from P10, who shared
HLA-A9 with the tumour cell line PC-3. Results are given as specific lysis of
target cells. The prostate cancer cell line PC-3 and mRNA-transfected DCs
are killed, but no lysis when HLA-matched EB cell lines were used as
targets. The ratio of effector: target in this experiment was 25:1. The
results are recorded as mean lysis of triplicate with s.e.m. indicated on the
bars.
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sevidence indicating that loading a broad spectrum of antigens
rather than single antigens onto DCs potentially may give rise to
more efficient anticancer immune responses (Nencioni et al, 2003;
Kalady et al, 2004). In the present study, we used mRNA isolated
from three human prostate cancer cell lines instead of primary
tumour from individual patient as a source of polyvalent prostate
cancer antigens. This approach was chosen due to lack of sufficient
biopsy material and has some disadvantages. The two most
important being that certain individual antigens present in the
patient’s own tumour may be absent from the vaccine and that
the vaccine contains numerous irrelevant antigens, such as
allo-HLA antigens and minor antigens encoded by a broad array
of polymorphisms. The absence of important individual antigens is
a general flaw in the majority of vaccine approaches, including all
of the molecularly defined vaccines except those that represent
antigens encoded by mutations such as K-Ras mutations (Gjertsen
et al, 1997). We believe that this aspect to some extent has been
taken care of in this study by combining several different prostate
cancer cell lines. The prostate cancer cell lines used were selected
so as to include one cell line (LNCaP) secreting a known prostate
cancer antigen PSA and the two other that represent androgen-
resistant cancer. The presence of allo-HLA antigens has been used
as nonspecific antigens in other approaches (Marten et al, 2003),
and may enhance the response rather than interfering negatively.
However, on the other hand, such T-cell responses may obscure
the specific responses and make interpretation of the T-cell data
more difficult.
We here document that sufficient number of vaccine quality
DCs could be generated successfully in all 20 patients enrolled.
Vaccination was well tolerated by the administration of both i.d.
and i.n. routes. No systemic toxicity was observed. Therefore,
using tumour cell line mRNA-transfected DCs as cancer vaccine is
safe.
Although the results from the in vitro T-cell tests and the in vivo
DTH reactions did not completely correlate to each other, the
main observation were very similar. Specific T-cell responses were
obtained in more than half of the patients. The nature of the
immune response was not studied in detail in this clinical study,
but in a preclinical evaluation, we analysed a broad range of
cytokines using the Bioplex system. These results demonstrated
that a broad spectrum of cytokines was produced in the in vitro-
generated T-cell response (LJ Mu et al, unpublished; Kyte et al,
2005) All of the patients who mounted a specific T-cell response
also developed a component of MLR reactive cells recognising
DCn. This also held true for most of the patients who failed to raise
a specific T-cell component. This response was clearly vaccine
dependent since very little reactivity was observed in prevaccine
samples. Based on a review of the results from clinical DC vaccine
trials published, this finding was unexpected, but similar results
have recently been published in a non-small-cell lung cancer DC
vaccine trial (Hirschowitz et al, 2004). Evidence for some
prevaccine T cells response specific for DCt was also observed in
three patients (Figures 2 and 3), indicating that a cellular immune
response to some prostate cancer antigens might be induced
spontaneously during the disease process. Reactivity against
known candidate prostate cancer antigens such as PSA will be
tested in an attempt to characterise the response in more detail.
In patients with progressive prostate cancer, the rise in serum
PSA is associated with an exponential growth rate (log-linear)
(Schmid et al, 1993; Patel et al, 1997). This was also seen in all our
patients at study entry. Of six patients with PSA higher than
100mgl
 1 at entry, there were only two developing immune
response to the vaccine. Of the 13 patients with PSA lower than
100mgl
 1 at entry, 10 showed positive immune response. Patients
with lower PSA tended to give a higher level of response. In this
study, it appears that i.d. injections gave better T-cell responses
(eight of nine) than those given i.n. administration (four of 10).
However since the i.d. group had lower median PSA (18.9mgl
 1)
than the i.n. group (median 112.2mgl
 1), we cannot presently
conclude that one route of injection is better than the other. Using
level of PSA as a surrogate marker for clinical response, 13 patients
demonstrated a decrease in PSA log slope. In some patients,
changes in PSA were only observed after boost injection(s),
indicating that repeated vaccinations over a longer period might be
required for clinical efficacy. Similar results were recently also
reported in a clinical study involving prostate cancer patients
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Since one component of the mRNA used in this trial is encoding
PSA, it may be argued that a change in log slope PSA may result
from the induction of PSA-specific antibodies by the vaccine. We
did not measure PSA antibodies in the serum of our patients, but
others using different forms of vaccines against PSA have failed to
induce such antibodies (Barrou et al, 2004; Kaufman et al, 2004).
In light of the high average PSA level in the patients in the present
study, we find it unlikely that the amount of PSA produced by DCt
would contribute much to the total PSA level in serum and hence
the stimulation of B cells in the patients.
In prostate cancer patients, DCs loaded with different types of
antigens have been used as vaccines. These antigens include
recombinant mouse prostate-acid phosphatase (PAP) (Fong et al,
2001), human PAP (Small et al, 2000), PSA proteins or RNA
(Heiser et al, 2002; Barrou et al, 2004), PSMA peptides (Tjoa et al,
1996), allogeneic tumour lysate (Pandha et al, 2004) and RNA
amplified from autotumour cells (Heiser et al, 2001). In general,
DC vaccination turns out to be safe to patients and evidence for
clinical benefit is accumulating. Comparisons of clinical effects
among the different trials are difficult since the clinical stages of
the patients studied are not the same in the individual protocols.
The approach followed by Pandha et al is very similar to the one
used by us, with the major difference that cell lysates rather than
mRNA was used as a source of antigen. Thus, they used two of the
three cell lines included in our protocol (LNCaP and DU 145). In
their study, they observed a similar frequency of immune
responders but a somewhat smaller clinical response, as only
three of the nine patients showed a fall in PSA or reduction in PSA
velocity. The latter may be the result of giving lower numbers of
DCs and fewer injections, as some of the patients in our study only
showed an effect on PSA velocity after booster vaccinations.
Although the number of patients in both studies is small, the
results of the two studies point in the same direction, indicating
that the use of a panel of allogeneic prostate cancer cells may be
represent an alternative to autologous tumour vaccines. To our
knowledge, this is the first report of a clinical trial using mRNA
from different cancer cell lines, representing a broad repertoire of
prostate cancer antigens. The correlation between T-cell responses
and a favourable early clinical outcome encourages further studies
involving patients in earlier stage of the disease. It would also be of
interest to perform a two-arm study comparing the efficacy of DCs
loaded with either tumour cell lines mRNA or lysate from the same
cell lines.
In order to further improve the clinical effect of our vaccination
approach, several issues needs to be addressed. Since some
patients had clinical responses only after booster vaccination, this
indicates that longer treatment periods may be needed to get full
effect of the vaccine. To intensify the immune response, shorter
intervals between each boost vaccination may also have effect.
Furthermore, it has been shown that less than 1% DCs injected i.d.
can migrate to secondary lymph nodes (Morse et al, 1999). This
means that the ‘active dose’ of the vaccine in our case is less than
2 10
5 DCs. Clearly, there is room for much improvement here.
Since the function and the maturation stage of DCs can influence
the vaccine results greatly (Jonuleit et al, 2001), a definite
establishment of the DC phenotype that correlates with good
clinical responses is needed. More recent trials in our institution
concentrate on using Toll-like receptor 7 agonists (Imiquimod)
applied to the skin to enhance the migration of DCs, and
enhancement of the T-cell responses by infusion of cytokines,
for example, IL-2 in combination with the DC vaccines.
ACKNOWLEDGEMENTS
This study was supported by a gene therapy grant from the
Norwegian Department of Health and by The Norwegian Cancer
Society (JAK). We thank Inger-Lise Ha ˚kensen, Anne Brunsvig,
Kirsti Hønna ˚shagen and Sigurd Borgen for the excellent work on
DCs generation; the nurses Kristin Øwre and Lone Hegg for patient
care.
REFERENCES
Barrou B, Benoit G, Ouldkaci M, Cussenot O, Salcedo M, Agrawal S,
Massicard S, Bercovici N, Ericson ML, Thiounn N (2004) Vaccination of
prostatectomized prostate cancer patients in biochemical relapse, with
autologous dendritic cells pulsed with recombinant human PSA Cancer.
Immunol Immunother 53: 453–460
Eaton JD, Perry MJ, Nicholson S, Guckian M, Russell N, Whelan M, Kirby
RS (2002) Allogeneic whole-cell vaccine: a phase I/II study in men with
hormone-refractory prostate cancer. BJU Int 89(1): 19–26
Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman
EG (2001) Dendritic cell-based xenoantigen vaccination for prostate
cancer immunotherapy. J Immunol 167: 7150–7156
Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G (1997)
Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras
(12Val) peptide vaccination of a patient, recognize 12Val-dependent
nested epitopes present within the vaccine peptide and kill autologous
tumour cells carrying this mutation. Int J Cancer 72: 784–790
Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, Cannistra S, Avigan D,
Kufe D (2000) Fusions of human ovarian carcinoma cells with
autologous or allogeneic dendritic cells induce antitumor immunity.
J Immunol 165: 1705–1711
Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm
P, Niedzwiecki D, Gilboa E, Vieweg J (2002) Autologous dendritic cells
transfected with prostate-specific antigen RNA simulate CTL responses
against metastatic prostate tumors. J Clin Invest 109: 409–417
Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, Gilboa
E (2000) Human dendritic cells transfected with RNA encoding prostate-
specific antigen stimulate prostate-specific CTL responses in vitro.
J Immunol 164: 5508–5514
Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, Boczkowski
D, Nair SK, Ballo MS, Gilboa E, Vieweg J (2001) Induction of polyclonal
prostate cancer-specific CTL using dendritic cells transfected with
amplified tumor RNA. J Immunol 166: 2953–2960
Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J (2004)
Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin
Oncol 22: 2808–2815
Hrouda D, Todryk SM, Perry MJ, Souberbielle BE, Kayaga J, Kirby RS,
Dalgleish AG (2000) Allogeneic whole-tumour cell vaccination in the rat
model of prostate cancer. BJU Int 86(6): 742–748
Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge
TB, Paragnik L, Kandemir A, Lee PP, Schuler G, Knop J, Enk AH (2001)
A comparison of two types of dendritic cell as adjuvants for the
induction of melanoma-specific T-cell responses in humans following
intranodal injection. Int J Cancer 93(2): 243–251
Kalady MF, Onaitis MW, Emani S, Abdul-Wahab Z, Pruitt SK, Tyler DS
(2004) Dendritic cells pulsed with pancreatic cancer total tumor RNA generate
specific antipancreatic cancer T cells. J Gastrointest Surg 8(2): 175–182
Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, Whiteside
TL, Schlom J, Wilding G, Weiner LM (2004) Phase II randomized
study of vaccine treatment of advanced prostate cancer (E7897): A Trial
of the Eastern Cooperative Oncology Group. J Clin Oncol 22: 2122–2132
Kyte JA, Kvalheim G, Aamdal S, Saeboe-Larssen S, Gaudernack G (2005)
Preclinical full-scale evaluation of dendritic cells transfected with
autologous tumor-mRNA for melanoma vaccination. Cancer Gene Ther
12: 579–591
Marten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R,
Flieger D, Hanfland P, Von Ruecker A, Eis-Hubinger AM, Muller S,
Schwaner I, Lohmann U, Heylmann G, Sauerbruch T, Schmidt-Wolf IG
(2003) Allogeneic dendritic cells fused with tumor cells: preclinical
results and outcome of a clinical phase I/II trial in patients with
metastatic renal cell carcinoma. Hum Gene Ther 14: 483–494
Dendritic cell vaccine for prostate cancer
LJ Mu et al
755
British Journal of Cancer (2005) 93(7), 749–756 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sMorse MA, Coleman RE, Akabani G, Niehaus N, Coleman D,
Lyerly HK (1999) Migration of human dendritic cells after in-
jection in patients with metastatic malignancies. Cancer Res 59:
56–58
Mu LJ, Gaudernack G, Saeboe-Larssen S, Hammerstad H, Tierens A,
Kvalheim G (2003) A protocol for generation of clinical grade mRNA-
transfected monocyte-derived dendritic cells for cancer vaccines. Scand J
Immunol 58: 578–586
Nencioni A, Muller MR, Grunebach F, Garuti A, Mingari MC, Patrone F,
Ballestrero A, Brossart P (2003) Dendritic cells transfected with tumor
RNA for the induction of antitumor CTL in colorectal cancer. Cancer
Gene Ther 10(3): 209–214
Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C,
Dalgleish AG (2004) Dendritic cell immunotherapy for urological cancers
using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II
study. BJU Int 94(3): 412–418
Patel A, Dorey F, Franklin J, deKernion JB (1997) Recurrence patterns after
radical retropubic prostatectomy: clinical usefulness of prostate specific
antigen doubling times and log slope prostate specific antigen. J Urol 158:
1441–1445
Schmid HP, McNeal JE, Stamey TA (1993) Observations on the doubling
time of prostate cancer: the use of serial prostate-specific antigen in
patients with untreated disease as a measure of increasing cancer
volume. Cancer 71: 2031–2040
Shaffer DR, Scher HI (2003) Prostate cancer: a dynamic illness with shifting
targets. Lancet Oncol 4: 407–414
Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH
(2000) Immunotherapy of hormone-refractory prostate cancer with
antigen-loaded dendritic cells. J Clin Oncol 18: 3894–3903
Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, Sichi S,
Niedzwiecki D, Boczkowski D, Gilboa E, Vieweg J (2005) Telomerase
mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and
CD4+ T cell responses in patients with metastatic prostate cancer.
J Immunol 174: 3798–3807
Tjoa B, Boynton A, Kenny G, Ragde H, Misrock SL, Murphy G (1996)
Presentation of prostate tumor antigens by dendritic cells stimulates
T-cell proliferation and cytotoxicity. Prostate 28: 65–69
Trefzer U, Weingart G, Chen Y, Herberth G, Adrian K, Winter H, Audring
H, Guo Y, Sterry W, Walden P (2000) Hybrid cell vaccination for cancer
immune therapy: first clinical trial with metastatic melanoma. Int J
Cancer 85: 618–626
Vonderheide RH, Hahn WC, Schultze JL, Nadler LM (1999) The telomerase
catalytic subunit is a widely expressed tumor-associated antigen
recognized by cytotoxic T lymphocytes. Immunity 10: 673–679
Dendritic cell vaccine for prostate cancer
LJ Mu et al
756
British Journal of Cancer (2005) 93(7), 749–756 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s